Last updated: 2026-09-13 16:39:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CureVac N.V. (CVAC) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
CureVac N.V. (CVAC) last closed at $-- as of --, -- from the previous close of $--.
During the latest regular trading session, CVAC traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.
Over the past seven days, CureVac N.V. (CVAC) moved from $4,25 to $4,66, representing a gain of 9,65% ($0,41).
The stock traded between $4,24 and $4,68 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1,03 million shares, down versus the previous seven-day period, indicating lower trading activity.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
| Employees | 1088 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CureVac N.V. (CVAC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.